SKIN TESTING WITH PENICILLOATE AND PENILLOATE PREPARED BY AN IMPROVEDMETHOD - AMOXICILLIN ORAL CHALLENGE IN PATIENTS WITH NEGATIVE SKIN-TEST RESPONSES TO PENICILLIN REAGENTS
E. Macy et al., SKIN TESTING WITH PENICILLOATE AND PENILLOATE PREPARED BY AN IMPROVEDMETHOD - AMOXICILLIN ORAL CHALLENGE IN PATIENTS WITH NEGATIVE SKIN-TEST RESPONSES TO PENICILLIN REAGENTS, Journal of allergy and clinical immunology, 100(5), 1997, pp. 586-591
Background: Penicillin skin testing has been limited by the lack of co
mmercially available penicilloate and penilloate reagents. Objective:
This project was proposed to produce a stable, well-characterized supp
ly of penicilloate and penilloate for intrastate use by our health mai
ntenance organization and to document clinical safety and efficacy. Me
thods: An improved method of extraction for penicilloate and penilloat
e, which changed the solvents used during recrystallization, was devel
oped, With these newly prepared reagents, penicillin skin testing was
performed on 348 subjects. Skin testing was immediately followed by an
oral challenge of 250 mg of amoxicillin in 215 of 288 (75%) subjects
displaying a negative response to a battery of penicillin skin tests.
Results: Nuclear magnetic resonance and mass spectrometry of the newly
produced penicilloate and penilloate showed no evidence of organic co
ntamination. Penicillin skin testing resulted in 17.2% (60 of 348) pos
itive test results, with 20% of the subjects with positive results onl
y responding to the newly produced minor determinants, The rate of mil
d adverse reactions to penicillin skin testing was 1.1% (4 of 348). Th
e rate of mild acute adverse reactions was 5.1% (11 of 215), and the d
elayed reaction rate was 0.9% (2 of 215) with the amoxicillin challeng
e. Conclusions: This improved penicillin minor determinant extraction
method allows for the reproducible production of very pure preparation
s of penicilloate and penilloate. Large-scale penicillin skin testing,
followed by amoxicillin challenge if results are negative is feasible
in a large group model health maintenance organization operating with
in a single state with the use of internally produced penicilloate and
penilloate and commercially available penicillin, amoxicillin, and pe
nicilloyl polylysine.